Optimized Bee Venom Peptide Melittin Shows Promise Against Ulcerative Colitis in Mice | Research

The takeaway

Chemically stabilized melittin, a bee venom peptide, demonstrated significant anti-ulcerative colitis effects in mice through enhanced stability and reduced toxicity compared to the natural peptide.

Stability-optimized
Chemical modifications made melittin resistant to protease degradation while maintaining anti-colitis activity

What the researchers found

Stability-optimized melittin variants maintained anti-inflammatory activity while resisting protease degradation, significantly reducing ulcerative colitis severity in a mouse model.

Why it matters

Ulcerative colitis affects millions worldwide, and current treatments have limited efficacy and significant side effects. Bee venom peptides are a rich source of anti-inflammatory compounds, but their therapeutic development has been limited by poor stability. This study shows that chemical optimization can overcome this barrier.

The numbers in context

PCJ-675 showed improved proteolytic stability compared to native melittin. Tested in DSS-induced ulcerative colitis mouse model. Administered orally. Reduced colon shortening and suppressed inflammation markers (TLR4/NF-kB pathway).

How the study worked

Animal study involving chemical synthesis and optimization of melittin variants for stability, followed by protease resistance testing and evaluation in a mouse ulcerative colitis model for efficacy and safety.

Who was studied

DSS-induced ulcerative colitis mouse model

What this study cannot tell us

Animal study only — mouse UC model may not fully predict human response; toxicity profile of modified melittin needs thorough assessment; long-term safety unknown; delivery route and dosing for clinical use not optimized; cost of peptide synthesis and modification may be high.

How to read the evidence

Preclinical animal study with peptide engineering component. Demonstrates proof-of-concept but is early in the drug development pipeline.

When this study was published

Published in 2025, reflecting growing interest in venom-derived peptide therapeutics.

The bigger picture

This study demonstrates a general strategy for advancing venom-derived peptides into drug candidates. The stability-optimization approach could be applied to many other bioactive peptides from venoms and other natural sources that have been shelved due to poor pharmacokinetic properties.

Questions still open

What is the optimal delivery route for stabilized melittin in UC — oral, rectal, or systemic?
How does the modified peptide's safety profile compare to established UC treatments?
Could the stability-optimization approach be applied to other venom-derived anti-inflammatory peptides?

Common questions

Could bee venom really treat inflammatory bowel disease?

Melittin, the main component of bee venom, has strong anti-inflammatory properties. The challenge has been that it breaks down too quickly in the body to be useful as a drug. This study solved that by chemically modifying the peptide to make it more stable while keeping its healing properties.

Is it safe to use venom-derived medications?

The therapeutic peptide is a purified, modified version of just one component of bee venom — not the whole venom. Many approved drugs are derived from venoms (like the blood pressure drug captopril from snake venom). Careful modification and testing ensure the beneficial effects are kept while reducing toxicity.

Read the original research

Efficient synthesis, stability-guided optimization and anti-ulcerative colitis evaluation of bee venom peptide melittin.

Bioorganic & medicinal chemistry letters, 128, 130357

View on PubMed ↗Publisher’s paper ↗

Citation

Pang, Cheng-Jian; Yao, Jing-Fang; Lv, Qiu-Lan; Zhang, Li-Ze; Yu, Qian-Yao; Zeng, Li; Qi, Yun-Kun. (2025). Efficient synthesis, stability-guided optimization and anti-ulcerative colitis evaluation of bee venom peptide melittin.. Bioorganic & medicinal chemistry letters, 128, 130357. https://doi.org/10.1016/j.bmcl.2025.130357